新辅助化疗不影响联合肝脏离断和门静脉结扎分阶段肝切除术的残肝生长与结局
该研究基于国际ALPPS注册登记(NCT01924741)2012—2016年442例结直肠癌肝转移患者,回顾性分析新辅助化疗类型与剂量对残肝肥大及临床结局的影响。结论认为新辅助化疗(包括单克隆抗体)不负面影响残肝生长,潜在ALPPS候选者应考虑新辅助化疗。
要点
- 新辅助化疗(含单克隆抗体)不负面影响ALPPS术后残肝生长。
- 各化疗组间残肝肥大指标均无统计学差异。
核心结论
- 新辅助化疗包括单克隆抗体不负面影响残肝生长。
- 潜在ALPPS候选的结直肠癌肝转移患者应考虑新辅助化疗。
研究设计与样本
- 国际ALPPS注册登记(NCT01924741)回顾性分析,纳入2012—2016年442例结直肠癌肝转移患者。
- 按化疗类型与剂量分组:无化疗、1种方案化疗、>1种方案、化疗加单克隆抗体。
- 分析残肝肥大(绝对增加、百分比增加、动力学增长率)与临床结局。
主要发现
- 残肝增大74%—92%,最大增幅见于1种方案化疗组。
- 残肝增加毫升数241 mL(>1种方案组)至306 mL(1种方案组)。
- 动力学增长率为每周14%—18%,1种方案化疗组最高。
- 各化疗组间残肝肥大各项指标均无统计学显著性差异。
临床怎么用
- 结直肠癌肝转移拟行ALPPS者不应因新辅助化疗而排除手术候选资格。
- 新辅助化疗(含单克隆抗体)可安全用于ALPPS术前准备,不影响残肝增生。
局限性
- 回顾性研究设计。
- 基于注册登记数据,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The only potentially curative treatment for patients with colorectal liver metastases is hepatectomy. Associating liver partition and portal vein ligation for staged hepatectomy has emerged as a method of treatment for patients with inadequate future liver remnant. One concern about associating liver partition and portal vein ligation for staged hepatectomy is that preoperative chemotherapy may negatively affect the volume increase of the future liver remnant and outcomes. METHODS: This study from the International Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy Registry (NCT01924741) includes 442 patients with colorectal liver metastases registered from 2012-2016. Future liver remnant hypertrophy (absolute increase, percent increase, and kinetic growth rate) and clinical outcome were analyzed retrospectively in relation to type and amount of chemotherapy. The analyzed groups included patients with no chemotherapy, 1 regimen of chemotherapy, >1 regimen, and a group that received monoclonal antibodies in addition to chemotherapy. RESULTS: Ninety percent of the patients received neoadjuvant oncologic therapy including 42% with 1 regimen of chemotherapy, 44% with monoclonal antibodies, and 4% with >1 regimen. Future liver remnant increased between 74-92% with the largest increase in the group with 1 regimen of chemotherapy. The increase in milliliters was between 241 mL (>1 regimen) and 306 mL (1 regimen). Kinetic growth rate was between 14-18% per week and was greatest for the group with 1 regimen of chemotherapy. No statistical significance was found between the groups with any of the measurements of future liver remnant hypertrophy. CONCLUSION: Neoadjuvant chemotherapy, including monoclonal antibodies, does not negatively affect future liver remnant growth. Patients with colorectal liver metastases who might be potential candidates for associating liver partition and portal vein ligation for staged hepatectomy should be considered for neoadjuvant chemotherapy.
引用
- Hasselgren K, Malagò M, Vyas S, et al. Neoadjuvant chemotherapy does not affect future liver remnant growth and outcomes of associating liver partition and portal vein ligation for staged hepatectomy. Surgery. 2017. PMID: 28081953. doi:10.1016/j.surg.2016.11.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。